Stifel Financial Corp Immunovant, Inc. Transaction History

Stifel Financial Corp

  • $93.2 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021
SELL
$13.08 - $49.6 $170,000 - $644,651
-12,997 Closed
0 $0
Q4 2020

Feb 12, 2021
SELL
$36.36 - $52.71 $55,158 - $79,961
-1,517 Reduced 10.45%
12,997 $600,000
Q3 2020

Nov 16, 2020
BUY
$22.61 - $38.9 $328,161 - $564,594
14,514 New
14,514 $511,000

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email